Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.
Also called NCT01131299
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 103 participants
- Registry
-
NCT01131299
-
- Other papers using this trial's data
- Randomized double blind clinical trial on the effect of oral α-cyclodextrin on serum lipids
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01131299. Randomized; double masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-10-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol
- Condition
- Cardiovascular Disease
- Intervention (Other)
- Placebo
- Intervention (Drug)
- Alpha cyclodextrin
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct01131299- Content hash
e72b73e21f4b951f7704a6f0a32a24e72afdd06a0887a4a8ab26b6fcea8e3099